Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
The unexpectedly low vaccine efficacy of Dengvaxia®, developed by Sanofi Pasteur, and a higher risk of severe diseases after vaccination among dengue-naive children or children younger than 6 years old, have cast skepticism about the safety of dengue vaccination resulting in the suspension of school...
Main Authors: | Jedhan Ucat Galula, Gielenny M. Salem, Gwong-Jen J. Chang, Day-Yu Chao |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-10-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2019.1643676 |
Similar Items
-
Comparable Accuracies of Nonstructural Protein 1- and Envelope Protein-Based Enzyme-Linked Immunosorbent Assays in Detecting Anti-Dengue Immunoglobulin G Antibodies
by: Jedhan Ucat Galula, et al.
Published: (2021-04-01) -
Frontiers in dengue virus research /
by: Hanley, Kathryn A., editor, et al.
Published: (c201) -
Dengue virus /
by: Rothman, Alan L., editor
Published: (c201) -
Determination of viral factors associated with dengue virus infection and disease severity
by: Suppiah, Jeyanthi
Published: (2019) -
An outbreak of dengue virus at Rio de Janeiro - 1986
by: Hermann G. Schatzmayr, et al.
Published: (1986-06-01)